Martin Juhl

This inventor holds 19 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: H. Lundbeck A/s. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin Juhl. Retrieved from https://idiyas.com/inventor/martin-juhl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 142(Granted Patents)

Company Filing History:

19 out of 513

H. Lundbeck A/s

patents

Years Active: 2020-2025

Loading Chart...

Areas of Expertise:

Catecholamine Prodrugs

Parkinson's Disease

MAGL Inhibitor

Solid Forms

Crystalline Forms

Manufacturing Process

Octahydrobenzoquinoline

Trihydroxy Compounds

Chemical Synthesis

Pharmaceutical Formulation

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479801 - Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5′:5,6]benzo[1,2-g]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (2025-11-25),

2. 12421271 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR, 10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2025-09-23),

3. 12398169 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2025-08-26),

4. 12391650 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2025-08-19),

5. 12384765 - Catecholamine prodrugs for use in the treatment of Parkinson's Disease (2025-08-12),

6. 12319710 - Catecholamine prodrugs for use in the treatment of Parkinson's diseases (2025-06-03),

7. 12226428 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2025-02-18),

8. 12152029 - Crystalline forms of a MAGL inhibitor (2024-11-26),

9. 11866410 - Process for the manufacturing of (6AR,10AR)-7-propyl-6,6A,7,8,9,10,10A,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4AR, 10AR)-1-propyl-1,2,3,4,4A,5,10,10A-octahydro-benzo[G]quinoline-6,7-diol (2024-01-09),

10. 11858954 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2024-01-02),

11. 11851456 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2023-12-26),

12. 11827665 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2023-11-28),

13. 11707476 - Catecholamine prodrugs for use in the treatment of parkinson's disease (2023-07-25),

14. 11168056 - Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol (2021-11-09),

15. 11130775 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2021-09-28),

Title: Inventor Spotlight: Martin Juhl, Pioneering Treatments for Neurodegenerative Diseases

Introduction:

Martin Juhl, a talented inventor based in Valby, Denmark, has made significant contributions to the field of pharmaceuticals with his innovative patents aimed at treating neurodegenerative diseases. With a total of 11 patents to his name, Juhl's work focuses on developing new processes and compounds for combating conditions like Parkinson's Disease.

Latest Patents:

Juhl's recent patents showcase his dedication to advancing treatment options for neurodegenerative diseases. His inventions include a novel process for manufacturing compounds essential for treating Parkinson's Disease, such as (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-g]quinoline. These compounds hold promise for patients suffering from such debilitating conditions.

Career Highlights:

Currently employed at H. Lundbeck A/S, a prominent pharmaceutical company, Martin Juhl continues to push the boundaries of pharmaceutical innovation. His expertise in drug development and patenting has garnered recognition within the industry, positioning him as a key player in the fight against neurodegenerative diseases.

Collaborations:

Juhl's innovative work is complemented by collaborations with esteemed colleagues such as Lisbet Kværnø and Mikkel Fog Jacobsen. Together, they form a dynamic team dedicated to driving forward new solutions for complex medical challenges, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, Martin Juhl stands out as a visionary inventor whose passion for developing pioneering treatments for neurodegenerative diseases is truly commendable. His patents not only demonstrate his technical prowess but also signify a deep commitment to improving the lives of individuals affected by these conditions. Juhl's contributions to the field of pharmaceuticals are invaluable, opening up new possibilities for the future of healthcare.

Profile summary based on public USPTO records.